Jakub F.
- Country
- Poland
- Department
- N/A
Research Overview
- Evaluation of Metformin's Effect on Unplanned Coronary Revascularization in Metformin-Naive Nondiabetic Patients Undergoing PCI for Acute Coronary Syndrome
- Assessment of Ticagrelor-Based De-Escalation Antiplatelet Strategies Versus Standard Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients
- Comparative Phase III Trial of Ferric Derisomaltose Versus No Intravenous Iron in Iron-Deficient Patients with Symptomatic Chronic Heart Failure
Data & Insights
Has run more than one trial at 222 of 843 partner sites.
Specializations
Coronary artery disease and acute coronary syndromes
Clinical research activity is centered on atherosclerotic cardiovascular disease, acute coronary syndrome, myocardial infarction, and stable angina, with attention to event prevention, ischemic risk reduction, and post-infarction cardiovascular protection.
- ASCVD
- Acute coronary syndrome
- Myocardial infarction
- Angina pectoris
- Lipoprotein(a)
Therapeutic interests also include lipid-driven cardiovascular risk, recurrent coronary events, and strategies aimed at reducing major adverse cardiovascular outcomes.
Heart failure and structural heart disease
The investigator is involved in studies of heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, heart failure with mildly reduced ejection fraction, and non-ischemic cardiomyopathy, including conditions linked with inflammation and left ventricular remodeling.
- HFrEF
- HFpEF
- HFmrEF
- Cardiomyopathy
- Left ventricular hypertrophy
Additional focus extends to acute and decompensated heart failure, symptom control, functional status, and prevention of worsening heart failure events.
Atrial fibrillation and antithrombotic care
Research involvement includes atrial fibrillation, especially in the setting of acute coronary syndrome and percutaneous coronary intervention, with emphasis on stroke prevention and balancing thrombotic and bleeding risk.
- Atrial fibrillation
- Oral anticoagulation
- Antiplatelet therapy
- Bleeding risk
- Coronary revascularization
The therapeutic landscape also covers dual antithrombotic approaches and rhythm-related outcomes in patients with complex cardiovascular comorbidity.
Hypertension and cardiorenal disease
Clinical trial activity includes hypertension, resistant hypertension, uncontrolled hypertension, chronic kidney disease, and systemic inflammation, reflecting interest in the overlap between vascular, renal, and metabolic disease.
- Resistant hypertension
- Chronic kidney disease
- Proteinuria
- Cardiorenal syndrome
- Inflammation
Therapeutic domains also include blood pressure control, kidney protection, and cardiovascular risk reduction in patients with combined renal and cardiometabolic disease.
Obesity, metabolic risk, and cardiometabolic prevention
The investigator is engaged in studies addressing obesity, overweight, type 2 diabetes, and related cardiovascular risk, with interest in therapies that link weight management to prevention of heart and kidney complications.
- Obesity
- Overweight
- Type 2 diabetes
- Cardiometabolic risk
- Kidney outcomes
Research also extends to lipid disorders such as elevated lipoprotein(a) and broader prevention of cardiovascular events in metabolically high-risk populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.